AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34979996 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived health scores
Number of subjects: 238
Study 33809544 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol botanical blend (PBB)
Number of subjects: 89
Study 33809544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 34028332 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic scene classification (ASC) activated
Number of subjects: 50
Study 34028332 — intervention group
Group type: COMPARATOR
Intervention: No ASC
Number of subjects: 50
Study 34028332 — intervention group
Group type: COMPARATOR
Intervention: Normal Hearing (NH) group
Number of subjects: 50
Study 32306953 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk basic (HRB) group - basic prevention regimen including oral-hygiene instruction, hands-on brushing practice, supervised daytime tooth brushing, sealant application, provision of toothbrush, fluoride-containing dentifrice, and a guidebook.
Number of subjects: 121
Study 32306953 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk intensive (HRI) group - intensified preventive regimen including F-varnish application, primary molar sealant, and silver diamine fluoride (SDF) application on carious lesions.
Number of subjects: 121
Study 32306953 — intervention group
Group type: COMPARATOR
Intervention: Low risk basic (LRB) group - basic prevention regimen similar to HRB group.
Number of subjects: 121
Study 32306953 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between HRB and HRI groups.
Number of subjects: 121
Study 35062997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0
Study 35062997 — intervention group
Group type: COMPARATOR
Intervention: Educational mindfulness based programme
Number of subjects: 0
Study 33386796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil infusion before balloon dilation or stent placement
Number of subjects: 120
Study 33386796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil infusion
Number of subjects: 120
Study 33386796 — intervention group
Group type: COMPARATOR
Intervention: Control group (balloon dilation and stent placement only)
Number of subjects: 120
Study 32969682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble representation - attention to statistical properties of distributions (range and mean)
Number of subjects: 0
Study 32969682 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenously increasing the salience of less extreme exemplars
Number of subjects: 0
Study 32969682 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenously increasing the salience of the distribution maximum
Number of subjects: 0
Study 32969682 — intervention group
Group type: EXPERIMENTAL
Intervention: Largest payment made to others solving the same math problems
Number of subjects: 0
Study 32969682 — intervention group
Group type: EXPERIMENTAL
Intervention: Largest payment made to others solving different verbal problems
Number of subjects: 0
Study 32195722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutrition supplement containing collagen peptides (10.0 g, once-a-day)
Number of subjects: 39
Study 36369793 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 0
Study 36369793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36369793 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 0
Study 33769598 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based predictive equation (25 kcal/kg/day)
Number of subjects: 0
Study 33769598 — intervention group
Group type: COMPARATOR
Intervention: Indirect calorimetry (IC)
Number of subjects: 0
Study 33769598 — intervention group
Group type: COMPARATOR
Intervention: Permissive underfeeding (50%-80% of requirements)
Number of subjects: 0
Study 33769598 — intervention group
Group type: COMPARATOR
Intervention: Full feeding (100%)
Number of subjects: 0
Study 32544794 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (Low-Int)
Number of subjects: 24
Study 32544794 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (Mod-Int)
Number of subjects: 24
Study 32544794 — intervention group
Group type: COMPARATOR
Intervention: Seated rest condition (REST)
Number of subjects: 24
Study 36127117 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 84
Study 36127117 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 84
Study 33217874 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Anxiety
Number of subjects: 74
Study 33217874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (suggested intervention)
Number of subjects: 74
Study 35354530 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel soaking solution (dexamethasone, gentamicin, and vitamin B12), soaked for 15 minutes, three times a day for four weeks.
Number of subjects: 60
Study 35354530 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid, soaked for 15 minutes, three times a day for four weeks.
Number of subjects: 60
Study 33441409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 15
Study 33441409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35700210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game (AVG) play
Number of subjects: 49
Study 35700210 — intervention group
Group type: COMPARATOR
Intervention: Sedentary video games (SVG)
Number of subjects: 49
Study 35700210 — intervention group
Group type: COMPARATOR
Intervention: Non-SVG sedentary behavior
Number of subjects: 49
Study 35700210 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 49
Study 35700210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjectively measured active play, social activities, other hobbies, television or computer/phone use
Number of subjects: 49
Study 33430613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan‐based polymers (CBP) nasal pack
Number of subjects: 50
Study 33430613 — intervention group
Group type: COMPARATOR
Intervention: Synthetic polyurethane
Number of subjects: 50
Study 32434504 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational program including video fragments, discussion, quizzes with tailored feedback, and an exercise filling out a registration form.
Number of subjects: 0
Study 33561824 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE (ice vest)
Number of subjects: 12
Study 33561824 — intervention group
Group type: COMPARATOR
Intervention: CON (no ice vest)
Number of subjects: 12
Study 34954100 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based screening with ENDPAC and CT imaging
Number of subjects: 12500
Study 34954100 — intervention group
Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 12500
Study 33725907 — intervention group
Group type: EXPERIMENTAL
Intervention: NEFN (novel EUS-guided fine needle biopsy)
Number of subjects: 56
Study 33725907 — intervention group
Group type: COMPARATOR
Intervention: CEFN (conventional EUS-guided fine needle aspiration)
Number of subjects: 56
Study 34144965 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 464
Study 34144965 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy (nb-UVB)
Number of subjects: 464
Study 34789181 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication+tDCS (n=15, receiving medications plus tDCS with 2 mA intensity over dorsolateral prefrontal cortex for 10 days, two sessions per day each for 20 min)
Number of subjects: 30
Study 34789181 — intervention group
Group type: COMPARATOR
Intervention: Medication (n=15, receiving mood stabilizers including 2-5 tables of 300 mg lithium, 200 mg sodium valproate, and 200 mg carbamazepine two times per day)
Number of subjects: 30
Study 34789181 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication+tDCS
Number of subjects: 30
Study 34789181 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 30
Study 35213714 — intervention group
Group type: EXPERIMENTAL
Intervention: GLWL‐01 (450 mg twice daily)
Number of subjects: 19
Study 35213714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 35213714 — intervention group
Group type: EXPERIMENTAL
Intervention: GLWL‐01
Number of subjects: 19
Study 35793862 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (including exercise training, nutritional support, respiratory physiotherapy, and psychological sessions)
Number of subjects: 146
Study 35793862 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-operative care
Number of subjects: 146
Study 32320767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal trials for systemic therapies for plaque psoriasis
Number of subjects: 69
Study 32320767 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials for FDA approval across various diseases
Number of subjects: 69
Study 32806954 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and levcromakalim
Number of subjects: 15
Study 32806954 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide and placebo
Number of subjects: 15
Study 32806954 — intervention group
Group type: COMPARATOR
Intervention: Placebo and placebo
Number of subjects: 15
Study 34910203 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg plus MTX
Number of subjects: 71
Study 34910203 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib 100 mg plus MTX
Number of subjects: 71
Study 34910203 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg
Number of subjects: 71
Study 34910203 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 71
Study 34910203 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib
Number of subjects: 71
Study 33997968 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care with secure attachment to foster mothers
Number of subjects: 138
Study 33997968 — intervention group
Group type: COMPARATOR
Intervention: Foster care with insecure attachment
Number of subjects: 138
Study 33997968 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 138
Study 34332159 — intervention group
Group type: EXPERIMENTAL
Intervention: True filtration
Number of subjects: 200
Study 34332159 — intervention group
Group type: COMPARATOR
Intervention: Sham filtration
Number of subjects: 200
Study 34244248 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group‐based lifestyle programme
Number of subjects: 1600
Study 34244248 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group‐based lifestyle programme and standard care
Number of subjects: 1600
Study 34244248 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1600
Study 32487336 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZT) plus Echinacea (5 ml oral suspension, 3 times daily for 10 consecutive days every month for 6 months)
Number of subjects: 300
Study 32487336 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (AZT) (60 mg/kg divided as 10 mg/kg/day over 6 consecutive days every month for 6 months)
Number of subjects: 300
Study 32487336 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 300
Study 36167423 — intervention group
Group type: EXPERIMENTAL
Intervention: COOLING (ice slushy ingestion and application of ice towels)
Number of subjects: 10
Study 36167423 — intervention group
Group type: COMPARATOR
Intervention: HOT (no cooling)
Number of subjects: 10
Study 33200737 — intervention group
Group type: COMPARATOR
Intervention: Conventional DMARDs (cyclophosphamide, mycophenolate mofetil, rituximab, tocilizumab, methotrexate)
Number of subjects: 142
Study 33200737 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (hypothetical based on SCOT/ASTIS results)
Number of subjects: 142
Study 33200737 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (actual, 4 patients)
Number of subjects: 142
Study 36244779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 to 0.7 µg/kg/h, DEX group)
Number of subjects: 24
Study 36244779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 24
Study 36244779 — intervention group
Group type: COMPARATOR
Intervention: Non-dexmedetomidine (non-DEX group)
Number of subjects: 24
Study 34741827 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ + activity tracker
Number of subjects: 60
Study 34741827 — intervention group
Group type: COMPARATOR
Intervention: Activity tracker only (attention-control group)
Number of subjects: 60
Study 35183923 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal swelling control intervention (MSI) including inelastic adjustable compression garment (CG), manual lymph drainage (MLD) massage, and home exercise program (HEP) for three weeks after TKA
Number of subjects: 16
Study 35183923 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 56; mean age 64.3 ± 9.3y)
Number of subjects: 16
Study 34273208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Number of subjects: 372
Study 34273208 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat
Number of subjects: 372
Study 33764851 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g soy protein (∼24–26/day genistein; ∼40–43/day total isoflavones)
Number of subjects: 16
Study 33764851 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 16
Study 33764851 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g soy protein
Number of subjects: 16
Study 34567596 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 113
Study 34567596 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 113
Study 34936044 — intervention group
Group type: EXPERIMENTAL
Intervention: OWN THE FUTURE: Pulling Together We Will (PTWW) intervention
Number of subjects: 806
Study 34936044 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 806
Study 36633795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1064 nm Nd: YAG laser (FxPico) treatment
Number of subjects: 24
Study 36633795 — intervention group
Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 24
Study 33497585 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation group (n=10)
Number of subjects: 20
Study 33497585 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigation group (n=10)
Number of subjects: 20
Study 32464321 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 19435
Study 32464321 — intervention group
Group type: COMPARATOR
Intervention: No Aspirin (Control)
Number of subjects: 19435
Study 35555254 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric normoxia (FiO2 = 0.21 ± 00)
Number of subjects: 12
Study 34360095 — intervention group
Group type: EXPERIMENTAL
Intervention: SEE-C (Simulation-based Empathy Enhancement program for Caregivers)
Number of subjects: 100
Study 34360095 — intervention group
Group type: COMPARATOR
Intervention: Control group (caregivers who did not experience SEE-C)
Number of subjects: 100
Study 35710102 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 12 intervals (1.5 min) at 85–90% HRmax, separated by 2 min at 55–60% HRmax, 3 sessions per week for 12 weeks
Number of subjects: 66
Study 35710102 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) - 42 min of cycling at 70% HRmax
Number of subjects: 66
Study 35710102 — intervention group
Group type: COMPARATOR
Intervention: Control group - no specific intervention mentioned
Number of subjects: 66
Study 33360089 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband noise at 55 dBA
Number of subjects: 45
Study 33360089 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband noise at 75 dBA
Number of subjects: 45
Study 33360089 — intervention group
Group type: COMPARATOR
Intervention: Ambient noise at 40 dBA
Number of subjects: 45
Study 33360089 — intervention group
Group type: EXPERIMENTAL
Intervention: All noise groups (55 dBA and 75 dBA)
Number of subjects: 45
Study 32869588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-separated moxibustion
Number of subjects: 62
Study 32869588 — intervention group
Group type: COMPARATOR
Intervention: Normal diet and proper physical exercise (Control)
Number of subjects: 62
Study 35863110 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-high gastric cancer in males
Number of subjects: 1307
Study 35863110 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-high gastric cancer in females
Number of subjects: 1307
Study 35863110 — intervention group
Group type: COMPARATOR
Intervention: MSS/MMRP gastric cancer in males
Number of subjects: 1307
Study 35863110 — intervention group
Group type: COMPARATOR
Intervention: MSS/MMRP gastric cancer in females
Number of subjects: 1307
Study 34357673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer everolimus‐eluting stents (BP-EES)
Number of subjects: 104
Study 34357673 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus‐eluting stents (DP-EES)
Number of subjects: 104
Study 35277414 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive tract (SDD)
Number of subjects: 324
Study 35277414 — intervention group
Group type: COMPARATOR
Intervention: Standard infection control measures
Number of subjects: 324
Study 36432444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum (BC)
Number of subjects: 242
Study 36432444 — intervention group
Group type: COMPARATOR
Intervention: Conventional Fortifier (CF)
Number of subjects: 242
Study 32070291 — intervention group
Group type: EXPERIMENTAL
Intervention: iCaPPS©
Number of subjects: 151
Study 32070291 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 151
Study 33127493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 498
Study 33127493 — intervention group
Group type: COMPARATOR
Intervention: Tape measure (TM)
Number of subjects: 498
Study 33127493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS) with no RNI
Number of subjects: 498
Study 33127493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS) with extensive RNI
Number of subjects: 498
Study 33127493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS) with ALND
Number of subjects: 498
Study 32142536 — intervention group
Group type: EXPERIMENTAL
Intervention: CanRisk prototype tool
Number of subjects: 75
Study 36443491 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lactalbumin (40 g)
Number of subjects: 13
Study 36443491 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip contraction (40% of maximal force)
Number of subjects: 13
Study 36443491 — intervention group
Group type: COMPARATOR
Intervention: Zein (isonitrogenous beverage)
Number of subjects: 13
Study 36443491 — intervention group
Group type: COMPARATOR
Intervention: Corn-starch (isocaloric beverage)
Number of subjects: 13
Study 33559440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional visual stimulation therapy
Number of subjects: 60
Study 33559440 — intervention group
Group type: COMPARATOR
Intervention: Conventional visual stimulation therapy
Number of subjects: 60
Study 32961528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 84
Study 32961528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 36503860 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated TADs
Number of subjects: 92
Study 36503860 — intervention group
Group type: COMPARATOR
Intervention: Uncoated TADs
Number of subjects: 92
Study 36503860 — intervention group
Group type: EXPERIMENTAL
Intervention: TADs placed on the left side
Number of subjects: 92
Study 33368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic intervention
Number of subjects: 386
Study 33368836 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 386
Study 32046910 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1116
Study 32046910 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 1116
Study 36102482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh tacked
Number of subjects: 63
Study 36102482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh fixed with fibrin glue
Number of subjects: 63
Study 36102482 — intervention group
Group type: COMPARATOR
Intervention: No mesh fixation
Number of subjects: 63
Study 35393316 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised acute physical exercise therapy prior to immune-chemotherapy infusion
Number of subjects: 30
Study 35393316 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home-based walking programme with an activity tracker
Number of subjects: 30
Study 35393316 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity recommendations and two nutritional assessments
Number of subjects: 30
Study 35393316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 36088501 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback profile
Number of subjects: 176
Study 36088501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 33654272 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG stove and cylinder refills as needed
Number of subjects: 1414
Study 33654272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan-assisted efficient biomass-burning cookstove
Number of subjects: 1414
Study 33654272 — intervention group
Group type: COMPARATOR
Intervention: Control arm (three-stone fires)
Number of subjects: 1414
Study 32451458 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal Analysis Using Summary Effect estimates (CAUSE)
Number of subjects: 0
Study 35294018 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced-sheet cooling (ISC)
Number of subjects: 0
Study 35294018 — intervention group
Group type: COMPARATOR
Intervention: Control (no ISC)
Number of subjects: 0
Study 36113009 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic pet
Number of subjects: 220
Study 36113009 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220